U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Pancreatic Adenocarcinoma

MedGen UID:
1662693
•Concept ID:
C0861741
•
Neoplastic Process

Definition

The reemergence of pancreatic adenocarcinoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer.
Chang SC, Hsu CP, Tsai CY, Liu YY, Liu KH, Hsu JT, Yeh TS, Yeh CN, Hwang TL
Medicine (Baltimore) 2016 Jul;95(30):e4191. doi: 10.1097/MD.0000000000004191. PMID: 27472688Free PMC Article
Oncologic treatment of pancreatic cancer.
O'Connell MJ
Mayo Clin Proc 1983 Jan;58(1):47-50. PMID: 6185802

Recent clinical studies

Etiology

Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K, Serikawa M, Ishii Y, Tsuboi T, Arihiro K, Murakami Y, Murashita J, Takahashi S
Langenbecks Arch Surg 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2. PMID: 37658871
Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.
Reddy AV, Hill CS, Sehgal S, He J, Zheng L, Herman JM, Meyer J, Narang AK
Clin Oncol (R Coll Radiol) 2022 Jun;34(6):386-394. Epub 2021 Dec 31 doi: 10.1016/j.clon.2021.12.014. PMID: 34974972
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH
Oncoimmunology 2021;10(1):1973710. Epub 2021 Sep 27 doi: 10.1080/2162402X.2021.1973710. PMID: 34595057Free PMC Article
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S
Anticancer Res 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P
Abdom Radiol (NY) 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. PMID: 28900703

Diagnosis

Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG, Chuong MD, Gomez AG, Bryant J, Contreras J, Romaguera T, Alvarez D, Kotecha R, Mehta MP, Gutierrez AN, Mittauer KE
Med Dosim 2021 Winter;46(4):384-388. Epub 2021 Jun 11 doi: 10.1016/j.meddos.2021.04.006. PMID: 34120803
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P
Abdom Radiol (NY) 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. PMID: 28900703
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX
J Hematol Oncol 2009 Mar 16;2:13. doi: 10.1186/1756-8722-2-13. PMID: 19291303Free PMC Article
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD
Ann Surg 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. PMID: 10235532Free PMC Article
Recurrent pancreatic adenocarcinoma: spiral CT evaluation following the Whipple procedure.
Bluemke DA, Abrams RA, Yeo CJ, Cameron JL, Fishman EK
Radiographics 1997 Mar-Apr;17(2):303-13. doi: 10.1148/radiographics.17.2.9084073. PMID: 9084073

Therapy

Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.
Reddy AV, Hill CS, Sehgal S, He J, Zheng L, Herman JM, Meyer J, Narang AK
Clin Oncol (R Coll Radiol) 2022 Jun;34(6):386-394. Epub 2021 Dec 31 doi: 10.1016/j.clon.2021.12.014. PMID: 34974972
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH
Oncoimmunology 2021;10(1):1973710. Epub 2021 Sep 27 doi: 10.1080/2162402X.2021.1973710. PMID: 34595057Free PMC Article
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S
Anticancer Res 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M
Radiat Oncol 2013 Jun 21;8:148. doi: 10.1186/1748-717X-8-148. PMID: 23799996Free PMC Article
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD
Ann Surg 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. PMID: 10235532Free PMC Article

Prognosis

Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K, Serikawa M, Ishii Y, Tsuboi T, Arihiro K, Murakami Y, Murashita J, Takahashi S
Langenbecks Arch Surg 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2. PMID: 37658871
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH
Oncoimmunology 2021;10(1):1973710. Epub 2021 Sep 27 doi: 10.1080/2162402X.2021.1973710. PMID: 34595057Free PMC Article
Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG, Chuong MD, Gomez AG, Bryant J, Contreras J, Romaguera T, Alvarez D, Kotecha R, Mehta MP, Gutierrez AN, Mittauer KE
Med Dosim 2021 Winter;46(4):384-388. Epub 2021 Jun 11 doi: 10.1016/j.meddos.2021.04.006. PMID: 34120803
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S
Anticancer Res 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD
Ann Surg 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. PMID: 10235532Free PMC Article

Clinical prediction guides

Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K, Serikawa M, Ishii Y, Tsuboi T, Arihiro K, Murakami Y, Murashita J, Takahashi S
Langenbecks Arch Surg 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2. PMID: 37658871
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH
Oncoimmunology 2021;10(1):1973710. Epub 2021 Sep 27 doi: 10.1080/2162402X.2021.1973710. PMID: 34595057Free PMC Article
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S
Anticancer Res 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P
Abdom Radiol (NY) 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. PMID: 28900703
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD
Ann Surg 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. PMID: 10235532Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...